Metabolic reprogramming and prognostic insights in molecular landscapes driven by glycolysis in ovarian cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Identifying glycolysis-related genes (GRGs) in ovarian cancer (OC) offers new prognostic insights. A ten-gene signature accurately predicts patient outcomes, guiding personalized treatment strategies for this fatal gynecological malignancy.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Ovarian cancer (OC) is a leading cause of cancer death, often diagnosed late with limited treatment options.
- Aberrant glycolysis, including the Warburg effect, drives OC progression, immune evasion, and microenvironment changes.
- Identifying glycolysis-related genes (GRGs) is crucial for understanding OC prognosis and developing new therapies.
Purpose Of The Study
- To identify differentially expressed GRGs in OC.
- To analyze the prognostic significance of GRGs and develop a predictive signature.
- To explore tumor microenvironment heterogeneity and potential therapeutic targets in OC.
Main Methods
- Utilized transcriptomic and clinical data from TCGA, GTEx, and GEO databases.
- Identified differentially expressed GRGs, analyzed prognostic values, and performed consensus clustering.
- Developed and validated a ten-gene GRG signature using LASSO-Cox regression; conducted immune and single-cell RNA sequencing analyses.
Main Results
- Identified 457 differentially expressed GRGs, with 30 significantly linked to OC prognosis.
- Characterized three molecular subtypes, with one showing the worst prognosis and activated tumor pathways.
- Developed and validated a robust ten-gene prognostic signature (LMCD1, L1CAM, MYCN, GALT, IDO1, RPL18, XBP1, LPAR3, RUNX3, PLCG1) with significant predictive efficacy.
Conclusions
- The ten-gene GRG signature provides a reliable tool for OC risk assessment and personalized treatment planning.
- Targeting glycolytic pathways presents a promising strategy to improve OC management and patient outcomes.
- Further experimental and clinical validation is required for translating these findings into practice.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Nearly all the energy used by cells comes from the bonds that make up complex organic compounds. These organic compounds are broken down into simpler molecules, such as glucose. As a result, cells extract energy from glucose over many chemical reactions—a process called cellular respiration.
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...